Abstract
Several cholinesterase (ChE) inhibitors have been labeled with carbon-11 for visualizing binding sites on acetylcholinesterase (AChE) by positron emission tomography (PET). Following intravenous injection of 1,2,3,4- tetrahydro-9-[11C]methylaminoacridine or [11C]donepezil, however, the radioactivity distribution does not reflect the regional distribution of AChE in the brain of animals, probably because these compounds have high non-specific binding and / or other specific binding sites in vivo in the brain. PET studies with [11C]physostigmine and [11C]CP-126,998 in the brain of healthy subjects have shown a radioactivity distribution corresponding to the regional distribution of AChE activity measured in postmortem human brains. These radiotracers may be useful for measuring the occupancy of binding sites on AChE by AChE inhibitors, and for investigating the cerebral pharmacokinetics of such therapeutic drugs. An alternative approach to map AChE is the use of acetylcholine analogue substrates. We have developed Nmethylpiperidinyl esters labeled with carbon-11 for quantitative measurement of AChE activity. Currently, two N- [11C]methylpiperidine esters, N-[11C]methylipiperidin-4-ylacetate (MP4A) and N-[11C]methylpiperidin-4-yl propionate (MP4P or PMP), have been used for clinical studies of Alzheimers disease and other neurodegenerative diseases. Both [11C]MP4A- and [11C]MP4P-PET have demonstrated not only the reduction of AChE activity in the cerebral cortex of patients with Alzheimers disease (AD) but also the inhibitory effects of donepezil and rivastigmine on AChE activity in the brain of AD patients. AChE imaging should prove useful for therapeutic monitoring of the effects of ChE inhibitors, including determination of the appropriate clinical doses of newly developed compounds, and can thus prompt the development of novel drugs targeting AChE.
Keywords: acetylcholine, acetylcholinesterase, butyrylcholinesterase, positron emission tomography, alzheimer disease, donepezil, physostigmine, rivastigmine
Current Pharmaceutical Design
Title: Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design
Volume: 10 Issue: 13
Author(s): Hitoshi Shinotoh, Kiyoshi Fukushi, Shin-ichiro Nagatsuka and Toshiaki Irie
Affiliation:
Keywords: acetylcholine, acetylcholinesterase, butyrylcholinesterase, positron emission tomography, alzheimer disease, donepezil, physostigmine, rivastigmine
Abstract: Several cholinesterase (ChE) inhibitors have been labeled with carbon-11 for visualizing binding sites on acetylcholinesterase (AChE) by positron emission tomography (PET). Following intravenous injection of 1,2,3,4- tetrahydro-9-[11C]methylaminoacridine or [11C]donepezil, however, the radioactivity distribution does not reflect the regional distribution of AChE in the brain of animals, probably because these compounds have high non-specific binding and / or other specific binding sites in vivo in the brain. PET studies with [11C]physostigmine and [11C]CP-126,998 in the brain of healthy subjects have shown a radioactivity distribution corresponding to the regional distribution of AChE activity measured in postmortem human brains. These radiotracers may be useful for measuring the occupancy of binding sites on AChE by AChE inhibitors, and for investigating the cerebral pharmacokinetics of such therapeutic drugs. An alternative approach to map AChE is the use of acetylcholine analogue substrates. We have developed Nmethylpiperidinyl esters labeled with carbon-11 for quantitative measurement of AChE activity. Currently, two N- [11C]methylpiperidine esters, N-[11C]methylipiperidin-4-ylacetate (MP4A) and N-[11C]methylpiperidin-4-yl propionate (MP4P or PMP), have been used for clinical studies of Alzheimers disease and other neurodegenerative diseases. Both [11C]MP4A- and [11C]MP4P-PET have demonstrated not only the reduction of AChE activity in the cerebral cortex of patients with Alzheimers disease (AD) but also the inhibitory effects of donepezil and rivastigmine on AChE activity in the brain of AD patients. AChE imaging should prove useful for therapeutic monitoring of the effects of ChE inhibitors, including determination of the appropriate clinical doses of newly developed compounds, and can thus prompt the development of novel drugs targeting AChE.
Export Options
About this article
Cite this article as:
Shinotoh Hitoshi, Fukushi Kiyoshi, Nagatsuka Shin-ichiro and Irie Toshiaki, Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design, Current Pharmaceutical Design 2004; 10 (13) . https://dx.doi.org/10.2174/1381612043384763
DOI https://dx.doi.org/10.2174/1381612043384763 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV-1 TAR RNA: The Target of Molecular Interactions Between the Virus and its Host
Current HIV Research NMDA Receptors and Learning and Memory Processes
Current Drug Targets Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design [<sup>18</sup>F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, <i>In Silico, In vitro</i> and <i>In vivo</i> Evaluations
Current Radiopharmaceuticals Editorial (Thematic Issue: “Infectious Diseases in Asia-Pacific: Historical and Contemporary Perspectives”)
Infectious Disorders - Drug Targets Myelin Injury and Degraded Myelin Vesicles in Alzheimer’s Disease
Current Alzheimer Research Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Memory Impairment
Current Alzheimer Research Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Turning Up the Pressure on Vascular Disease
Current Neurovascular Research Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Editorial: Advances in Understanding Alzheimer's Disease, and the Contributions of Current Alzheimer Research: Ten Years on and Beyond
Current Alzheimer Research Clinical Implication of Meissner’s Corpuscles
CNS & Neurological Disorders - Drug Targets Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Current Pharmaceutical Design Diet and Brain Health: Which Role for Polyphenols?
Current Pharmaceutical Design Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research